![ASM Microbe 2018: Nosopharm to present new first-in-class clinical candidate to tackle Enterobacteriaceae infections](https://ala.associates/wp-content/uploads/2022/04/Nosopharm50-Xenorhabdus-and-Photorhabdus-bacteira1-500x250-1.jpg)
![ASM Microbe 2018: Nosopharm to present new first-in-class clinical candidate to tackle Enterobacteriaceae infections](https://ala.associates/wp-content/uploads/2022/04/Nosopharm50-Xenorhabdus-and-Photorhabdus-bacteira1-500x250-1.jpg)
![Nosopharm renews its partnership with Inra](https://ala.associates/wp-content/uploads/2022/04/Nosopharm42-Investigating-Xenorhabdus-and-Photorhabdus-bacteria-500x250-1.jpg)
Nosopharm renews its partnership with Inra
![Genoscience Pharma extends its first clinical trial of GN561 in patients with advanced liver cancers to France](https://ala.associates/wp-content/uploads/2022/04/Genoscience-hopitaux-500x250-1.png)
Genoscience Pharma extends its first clinical trial of GN561 in patients with advanced liver cancers to France
![ASCO 2018: GamaMabs Pharma to present results from the First-In-Human clinical study of GM102 in gynecological cancers](https://ala.associates/wp-content/uploads/2017/10/SDegove-1080x675.jpg)
ASCO 2018: GamaMabs Pharma to present results from the First-In-Human clinical study of GM102 in gynecological cancers
![ASCO 2018: GamaMabs Pharma to present results from the First-In-Human clinical study of GM102 in gynecological cancers](https://ala.associates/wp-content/uploads/2017/10/SDegove-1080x675.jpg)
GamaMabs Pharma to present new data at AACR 2018
![Antibiotic resistance: Nosopharm and the University of Illinois at Chicago in Molecular Cell](https://ala.associates/wp-content/uploads/2018/04/ODLs-1080x675.png)
Antibiotic resistance: Nosopharm and the University of Illinois at Chicago in Molecular Cell
![Genoscience Pharma starts first-in-human dosing of GNS561 in patients with advanced liver cancer](https://ala.associates/wp-content/uploads/2018/04/HALFONPhilippe.png)
Genoscience Pharma starts first-in-human dosing of GNS561 in patients with advanced liver cancer
![Domain’s business model gains validation through Prexton’s acquisition by Lundbeck for up to $1.1 billion](https://ala.associates/wp-content/uploads/2018/03/Pascal-NEUVILLE_DOMAIN-Therapeutics_portrait-895x675.png)
Domain’s business model gains validation through Prexton’s acquisition by Lundbeck for up to $1.1 billion
![Lundbeck to acquire Prexton Therapeutics in a deal valued at up to €905 million](https://ala.associates/wp-content/uploads/2017/02/CONQUET-Francois-e1486458395645-1080x675.jpg)
Lundbeck to acquire Prexton Therapeutics in a deal valued at up to €905 million
![BCI Pharma receives €3.9M ($4.7M) in public and private funding; sets up laboratory](https://ala.associates/wp-content/uploads/2018/03/Dominique-Surleraux-1.png)